Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus

Singapore Medical Journal

Volumn 50, Issue 4, 2009, Pages 395-399

  Chogtu, Bharti ^a   Singh, N P ^b   Chawla, S ^c   Gupta, U ^c  

^a KASTURBA MEDICAL COLLEGE   (India)

^b Lok Nayak Jai Prakash Hospital   (India)

^c MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Blood pressure; Diabetes mellitus; Glimepiride; Lipid profile; Pioglitazone; Rosiglitazone

Indexed keywords

CHOLESTEROL; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; PIOZ; REZULT; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INDIA; LIPIDS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 65949101892     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. King H, Aubert RE, Herman WH. Global burden of diabetes 1995-2025; prevalence, numerical estimates and projections. Diabetes Care 1998; 21:1414-1431
2. Ginsberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: Beyond glucose level lowering. J Cardiovasc Risk 1999: 6:337-346
3. Heart Outcomes Prevention Evaluation Study Investigators. Effect of ramipiril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259 (Pubitemid 30068516)
4. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65:385-411. (Pubitemid 40227460)
5. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Non-hypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134:61-71.
6. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone versus glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 2008: 299:1561-1573
7. Yki-Järvinen H. Thiazolidinediones. N Eng J Med 2004; 351:1106-1118
8. Garg A. Dyslipoproteinemia and diabetes. Endocrinol Metab Clin North Am 1998; 27:613-625 (Pubitemid 28446951)
9. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001; 7:162-169 (Pubitemid 32514871)
10. Khan MA, St.Peter JV, Xue JL. A prospective, randomised comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25:708-711 (Pubitemid 41071191)
11. Chiquette E, Ramerez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164:2097-2104 (Pubitemid 39419498)
12. Wurch T, Junquero D, Delhon A, Pauwels J. Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor. Naunyn Schmiedebergs Arch Pharmacol 2002; 365:133-140 (Pubitemid 34253106)
13. Natham DM. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. Lancet 1998; 352:832-833
14. Kawasaki J, Hirano K, Nishimura J, Fujishima M, Kanaide H. Mechanism of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery. Circulation 1998; 98:2446-2452 (Pubitemid 28549790)
15. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26:172-178 (Pubitemid 36929012)
16. Füllert S, Schneider F, Haake E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind placebo-controlled study. J Clin Endocrinol Metab 2002; 87:5503-5506
17. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471 (Pubitemid 46919772)
18. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in a PROactive Study. (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289